71 results on '"Picci, P"'
Search Results
2. The sacral chordoma margin
3. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study
4. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
5. Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”
6. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
7. Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”
8. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
9. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
10. PO-340 Dysregulation of the TP53 network and PRC2 activity are independent poor prognostic factors in patients with malignant peripheral nerve sheath tumours
11. Histology and grading are important prognostic factors in synovial sarcoma
12. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
13. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
14. Primary extraskeletal myxoid chondrosarcoma of bone: Report of three cases and review of the literature
15. PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma
16. sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial
17. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome
18. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients
19. High-grade bone sarcomas with synchronous metastases in patients older than 40. Results of the European Bone over 40: Sarcoma Study (EURO.B.O.S.S.)
20. How a Clinical Trial Office can improve the independent Clinical Research: the Italian Sarcoma Group experience
21. Spontaneous healing of an osteochondroma fracture
22. OR8-6: The anti-IGF signaling agents increase the efficacy of Trabectedin in Ewing sarcoma
23. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression
24. Fdg Pet/Ct in Patients Treated with Neoadjuvant Chemotherapy for Localized Bone Sarcomas
25. 440: Genomic copy number changes and the prognostic impact of the encoded genes PTEN and BIRC5 in malignant peripheral nerve sheath tumours
26. Imaging of bone tumors for the musculoskeletal oncologic surgeon
27. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall
28. Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation
29. P03-13 Preclinical effectiveness of metformin in Ewing sarcoma
30. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients
31. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
32. CD99: A new mediator of osteoblastogenesis
33. Bone metastasis from primary carcinomas and sarcomas: Cell signaling kinase modulation by the neuroreticular axis
34. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
35. 134 Dissecting the mTOR pathway in osteosarcoma
36. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
37. Sarcome des parties molles
38. Synovial chondrosarcoma: Report of two cases and literature review
39. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
40. Tumor cell NG2 proteoglycan controls cancer progression through its interaction with host Collagen type VI
41. Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment
42. 546 POSTER Prognostic value of CCN3 in osteosarcoma and Ewing's sarcoma
43. Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing’s family tumours
44. Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999
45. Proteases and interleukin-6 gene analysis in 92 giant cell tumorsof bone
46. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells
47. Computed tomography of pulmonary metastases from osteosarcoma: The less poor technique. A study of 51 patients with histological correlation
48. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute
49. Simultaneous Paired Analysis of Numerical Chromosomal Aberrations and DNA Content in Osteosarcoma
50. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.